Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer.
Phase I: Feasibility and tolerability of IPI-NIVO combined with sacituzumab as first-line therapy for cisplatin-ineligible patients with metastatic urothelial carcinoma Phase II: To evaluate measurable disease overall response rate (ORR) of IPI-NIVO combined with sacituzumab as first-line therapy for cisplatin-ineligible patients with metastatic urothelial carcinoma. Phase I: 1. Measurable disease overall response rate (ORR) 2. Duration of response (DOR) 3. Progression-free survival (PFS) 4. Overall Survival (OS). Phase II 1) To evaluate progression-free survival (PFS). 2) Duration of response (DOR) 3) To evaluate Overall Survival (OS).4) To evaluate toxicities
Immunotherapy; Therapy (NOS)
BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sacituzumab Govitecan (); Yervoy (Ipilimumab)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.